| |
|
Global Hep Summit - Efficacy and Safety of Sofosbuvir/Velpatasvir in Treatment-Naïve, Non-Cirrhotic Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Three Phase 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
&
Global Hepatitis Summit, June 14-17th, 2018, Toronto, Canada
Sergio M. Borgia1, Ira M. Jacobsono, Edward J. Ganeo, Ola Weiland4, Eric Lawitz5, Nezam Afdhal6, Nelson Cheinquer7, John Wolf7, Joseph Llewellyn7, Steeve Houle7, Phil Troke7, Michael Mertens7, Evguenia Svarovskaia7, Gerald Crans7, Luisa M. Stamm7, Stephen D. Shafran8, Marc Bourliere9 and Jordan J. Feld10
oWilliam Osler Health System, Brampton Civic Hospital, Brampton, Ontario, Canada; oIcahn School of Medicine at Mount Sinai, New York, NY; oNew Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 4Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden;
5Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 6Beth Israel Deaconess Medical Center, Boston, MA; 7Gilead Sciences, Inc, Foster City, CA; 8University of Alberta, Edmonton, AB, Canada; 9Hospital Saint Joseph, Marseille, France; 10Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada
| |
| |
| |
|
|
|
